Klin Onkol 1995; 8(01): 16-19.
Summary
Standard treatment regimens for patients with bronchogenic small-cell as well as non-small-cell carcinomas contain cisplatin and etoposide. We describe experience with a more recent analog of cisplatin (carboplatin) in the treatment of such tumors. Twenty-nine patients with small-cell bronchogenic carcinoma were treated by a single intravenous administration of carboplatin (400 mg/m2), cyclophosphamide (400 mg/2) and doxorubicine (40 mg/m2). The pause berween chemotherapeutic cycles was 28 days. A complete remission was achieved in 42 °/o, partial remission in 48 % of patients. The progression of the disease in the course of the treatment was perceptible in only 10 % of patients.
Nineteen patients with non small-cell bronchogenic carcinoma were treated by a single intravenous administration of carboplatin (400 mg/m2), mitomycine-C (12 mg/m2) and vincristine (1,5 mg). The pause between the individual cycles was 28 days. Complete remission was not achieved in any patient. Partial and time-limited regression of the tumor and the alleviation of subjective complaints was observed in 80 % of patients. The results of the treatment by the above chemotherapeutic schemes containing carboplatin do not differ from literary results obtained by standard therapy (cisplatin and etoposide). Due to good tolerance and one-day administration the above schemes are suitable for out-patient treatment which, from the point of view of the quality of life, is more suitable for the patients than the treatment under hospitalization.
